Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 16, Number 3—March 2010
Research

Vaccine Preventability of Meningococcal Clone, Greater Aachen Region, Germany

Johannes EliasComments to Author , Leo M. Schouls, Ingrid van de Pol, Wendy C. Keijzers, Diana R. Martin, Anne Glennie, Philipp Oster, Matthias Frosch, Ulrich Vogel1, and Arie van der Ende1
Author affiliations: University of Wuerzburg, Wuerzburg, Germany (J. Elias, M. Frosch, U. Vogel); National Institute for Public Health and Environment (RIVN), Bilthoven, the Netherlands (L.M. Schouls, I. van de Pol); Academic Medical Center, Amsterdam, the Netherlands (W.C. Keijzers, A. van der Ende); Institute of Environmental Science and Research, Porirua, New Zealand (D.R. Martin, A. Glennie); Novartis Vaccines, Siena, Italy (P. Oster)

Main Article

Figure 4

Kernel density plots of age distribution of MT19/ST42 case-patients compared with the rest of the ST41/44 complex. The vertical gray line indicates 10 years.

Figure 4. Kernel density plots of age distribution of MT19/ST42 case-patients compared with the rest of the ST41/44 complex. The vertical gray line indicates 10 years.

Main Article

1These authors contributed equally to this article.

Page created: December 14, 2010
Page updated: December 14, 2010
Page reviewed: December 14, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external